LAMP1 and leukemia: Taking away the ATF4-mediated blockade, sorafenib allowed IRF7 activation and caused IL-15 transcription in the leukemia cells which caused an increase of CD8+ CD107a+ IFNγ+ T cells, which was connected to the increased elimination of leukemia cells by activated donor T cells [20] (Fig. 1).